NASDAQ: PTCT · Biotechnology
PTC Therapeutics (PTCT) fair value and price range
As of 16 Nov 2026, Faircurve's model values PTC Therapeutics (PTCT) at $74.62 a share. The stock last closed at $60.97, which puts the model's fair value 22.4% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 16 Nov 2026. PTC Therapeutics, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 16 Nov 2026 moved the fair value from $76.37 to $74.62 (-2.3%).
What the model makes of itThe price of $60.97 is 22.4% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 18 Feb 2027. Options prices imply a move of about 16% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give PTCT?
The calibrated range for PTCT over 63 trading days is $50.90 to $73.70. It sits around the last close, and its width comes from the volatility that PTCT's own options imply (55% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $46.51 to $113.95. In 61% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 16 Nov 2026
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development and commercialisation of innovative therapies for patients with rare genetic disorders.
Faircurve's model gives a fair value of $74.62 a share on 16 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $76.37, so the fair value moved -2.3%. The calibrated range over 63 trading days is $53.75 to $75.63, built from the volatility implied by the stock's options. The range is calibrated weekly against realised prices, using 8,038 past valuations refreshed on 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as low, so no verdict is shown. The grade covers how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
The model's overall quality score is 41 out of 100, a composite of six factors. Growth quality stands out at 62, with trailing revenue growth of 114.5% against a peer median of 33.9%. Profitability scores 20, with ROIC of -215.9% against a peer median of -14.0%. The model compares the company with Protagonist Therapeutics, Inc. (PTGX), Acadia Pharmaceuticals Inc. (ACAD), ADMA Biologics, Inc. (ADMA) and Vericel Corporation (VCEL).
Written from the figures on this page for the 16 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does PTCT report earnings, and how has the stock reacted?
PTC Therapeutics's next earnings report is scheduled for 18 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 12.7% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. PTCT's 30 day implied volatility works out to about 15.8% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across PTCT's last 8 reports, ignoring direction, was 8.6%.
What the options market has priced for a month's move in PTCT
How does PTCT score on business quality?
PTC Therapeutics's overall quality score is 41 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 20 | -215.9%ROIC | -14.0% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 50 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 62 | 114.5%Revenue growth, trailing | 33.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 54 | 0.0%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 44 | 0.73xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 25 | 24.2 ptsEBITDA margin downside volatility, 5y | 51.4 pts |
How does PTCT compare with similar companies?
The companies in biotechnology closest to PTC Therapeutics in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| LGND Ligand Pharmaceuticals Incorporated | $301.71 | $282.99 | -6.2% | Low evidence grade |
| ARWR Arrowhead Pharmaceuticals, Inc. | $44.21 | $53.67 | +21.4% | Low evidence grade |
| CYTK Cytokinetics, Incorporated | $53.17 | $63.03 | +18.5% | Low evidence grade |
| PTGX Protagonist Therapeutics, Inc. | $124.83 | $104.97 | -15.9% | Overvalued |
| ACAD Acadia Pharmaceuticals Inc. | $18.67 | $23.24 | +24.5% | Undervalued |
| KRYS Krystal Biotech, Inc. | $297.90 | $352.42 | +18.3% | Low evidence grade |
| ADMA ADMA Biologics, Inc. | $13.47 | $15.96 | +18.5% | Undervalued |
| VCEL Vericel Corporation | $57.48 | $65.96 | +14.8% | Fairly valued |
What the comparable companies' multiples alone would give for PTCT, the peer-implied price, is $152.96 a share on this run. The fair value weighs that against the company's own multiple.
PTC Therapeutics at a glance
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders.
- Market value
- $5.3B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $1.4B
- Consensus revenue growth, next fiscal year
- -23.7%
- Analysts with estimates
- 7
- Beta to the US market
- 0.68
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices PTC Therapeutics on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for PTCT was $76.37. As of 16 Nov 2026 it is $74.62, a change of -2.3%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about PTC Therapeutics's valuation
Is PTC Therapeutics stock undervalued or overvalued?
Faircurve's model puts PTCT's fair value at $74.62 a share against a last close of $60.97, as of 16 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is PTCT's fair value?
$74.62 a share as of 16 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $46.51 to $113.95.
What price range does the model give PTCT?
$50.90 to $73.70 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does PTC Therapeutics report earnings next?
The next report is scheduled for 18 Feb 2027. Companies can move their dates.
How much has PTCT moved on past earnings reports?
Across its last 8 reports the median two session move was 8.6%, ignoring direction. The largest was +13.3% around the report of 3 Nov 2026.
How confident is the model in this valuation?
The model's evidence grade for PTCT is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on PTCT
The model holds no idea open on PTCT today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on PTCT with their outcomes. A free account is enough.